Use of High-Flow Nasal Cannula in Patients With Pneumonia and Hypoxemic Respiratory Failure at Altitudes Above 2600 m: What Is the Best Predictor of Success?
Restricted accessResearch articleFirst published online September, 2022
Use of High-Flow Nasal Cannula in Patients With Pneumonia and Hypoxemic Respiratory Failure at Altitudes Above 2600 m: What Is the Best Predictor of Success?
Introduction: The use of high-flow nasal cannulas (HFNC) in patients with hypoxemic ventilatory failure reduces the need for mechanical ventilation and does not increase mortality when intubation is promptly applied. The aim of the study is to describe the behavior of HFNC in patients who live at high altitudes, and the performance of predictors of success/failure of this strategy. Methods: Prospective multicenter cohort study, with patients aged over 18 years recruited for 12 months in 2020 to 21. All had a diagnosis of hypoxemic respiratory failure secondary to pneumonia, were admitted to intensive care units, and were receiving initial management with a high-flow nasal cannula. The variables assessed included need for intubation, mortality in ICU, and the validation of SaO2, respiratory rate (RR) and ROX index (IROX) as predictors of HFNC success / failure. Results: One hundred and six patients were recruited, with a mean age of 59 years and a success rate of 74.5%. Patients with treatment failure were more likely to be obese (BMI 27.2 vs 25.5; OR: 1.03; 95% CI: .95-1.1) and had higher severity scores at admission (APACHE II 12 vs 20; OR 1.15; 95% CI: 1.06-1.24). Respiratory rates after 12 (AUC .81 CI: .70-.92) and 18 h (AUC .85 CI: .72-0.90) of HFNC use were the best predictors of failure, performing better than those that included oxygenation. ICU mortality was higher in the failure group (6% vs 29%; OR 8.8; 95% CI:1.75-44.7). Conclusions: High-flow oxygen cannula therapy in patients with hypoxemic respiratory failure living at altitudes above 2600 m is associated with low rates of therapy failure and a reduced need for mechanical ventilation in the ICU. The geographical conditions and secondary physiological changes influence the performance of the traditionally validated predictors of therapy success. Respiratory rate <30 proved to be the best indicator of early success of the device at 12 h of use.
GoligherEC, SlutskyAS. Not just oxygen? Mechanisms of benefit from high-flow nasal cannula in hypoxemic respiratory failure. Am J Respir Crit Care Med. 2017;195(9):1128–1131.
2.
RocaOCaraltBMessikaJSamperMSztrymfBHernándezG. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019;199:1368–1376.
3.
ImrayCBoothAWrightABradwellAAcute altitude illnesses. Br Med J.2011;343:d4943.
4.
HackettPHRoachRC. High-Altitude illness. N Engl J Med. 2001 ;345(2):107–114.
5.
RocaOHernándezGDíaz-LobatoSCarrataláJMGutiérrezRMMasclansJR. Current evidence for the effectiveness of heated and humidified high flow nasal cannula supportive therapy in adult patients with respiratory failure. Crit Care. 2016;20(1):109.
6.
DavisPRPattinsonKTSMasonNPRichardsPHillebrandtD. High altitude illness. J R Army Med Corps. 2005;151(4):243–249.
7.
FratJPThilleAWMercatA, et al.High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185–2196.
8.
FratJPRagotSGiraultC, et al.Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial. Lancet Respir Med. 2016;4(8):646–652.
9.
MandellLAWunderinkRGAnzuetoA, et al.Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72.
10.
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416.
11.
VincentJLMorenoRTakalaJ, et al.The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine. Intensive Care Med. 1996;22(7):707–710.
12.
JibajaMOrtiz-RuizGGarcíaF, et al.Hospital mortality and effect of adjusting PaO2/FiO2 according to altitude above the Sea level in acclimatized patients undergoing invasive mechanical ventilation. A multicenter study. Arch Bronconeumol. 2020;56(4):218–224. doi: 10.1016/j.arbres.2019.06.024. Epub 2019 Sep 30. PMID: 31582181.
13.
NiYNLuoJYuH, et al.Can high-flow nasal cannula reduce the rate of endotracheal intubation in adult patients with acute respiratory failure compared with conventional oxygen therapy and noninvasive positive pressure ventilation? A systematic review and meta-analysis. Chest. 2017;151(4):764–775.
14.
RicardJ-DMessikaJSztrymfBGaudryS. Impact on outcome of delayed intubation with high-flow nasal cannula oxygen: is the device solely responsible?Intensive Care Med. 2015;41(6):1157–1158.
15.
KangBJKohYLimCM, et al.Failure of highflow nasal cannula therapy may delay intubation and increase mortality. Intensive Care Med. 2015;41(4):623–632.
16.
KangelarisKNWareLBWangCY, et al.Timing of intubation and clinical outcomes in adults with acute respiratory distress syndrome. Crit Care Med. 2016;44(1):120–129.
17.
ChenWJanzDRShaverCMBernardGRBastaracheJAWareLB. Clinical characteristics and outcomes Are similar in ARDS diagnosed by oxygen saturation/Fio2 ratio compared With Pao2/Fio2 ratio. Chest. 2015;148(6):1477–1483. [cited 2016 May 18]
18.
RochwergBEinavSChaudhuriD, et al.The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practicne guideline. Intensive Care Med. 2020.46(12) 2226-2237.
19.
Artacho RuizRArtacho JuradoBCaballero GüetoF, et al.Predictors of success of high-flow nasal cannula in the treatment of acute hypoxemic respiratory failure. Med Intensiva. 2019. S0210-5691(19)30191-3. 45(2):80-87 English, Spanish. doi: 10.1016/j.medin.2019.07.012.
20.
MaitraSSomABhattacharjeeSAroraMKBaidyaDK. Comparison of high-flow nasal oxygen therapy with conventional oxygen therapy and noninvasive ventilation in adult patients with acute hypoxemic respiratory failure: a meta-analysis and systematic review. J Crit Care. 2016;35:138–144.
21.
LeeCCMankodiDShaharyarS, et al.High flow nasal cannula versus conventional oxygen therapy and non-invasive ventilation in adults with acute hypoxemic respiratory failure: a systematic review. Respir Med. 2016;121:100–108.
22.
TinelliVCabriniLFominskiyE, et al.High flow nasal cannula oxygen versus conventional oxygen therapy and noninvasive ventilation in emergency department patients: a systematic review and meta-analysis. J Emerg Med. 2019;57(3):322–328.
23.
BauerPRGajicONanchalR, et al.ICON Investigators (supplemental appendix 1). association between timing of intubation and outcome in critically ill patients: a secondary analysis of the ICON audit. J Crit Care. 2017;42:1–5.
24.
GrocottMMontgomeryHVercueilA. High-altitude physiology and pathophysiology: implications and relevance for intensive care medicine. Crit Care. 2007;11(1):203. doi:10.1186/cc5142
25.
Luks AM. Physiology in medicine: a physiologic approach to prevention and treatment of acute high-altitude illnesses. J Appl Physiol. 2015;118(5):509–519.
26.
Windsor JS, Rodway GW. Heights and haematology: the story of haemoglobin at altitude. Postgrad Med J. 2007;83(977):148–151. doi:10.1136/pgmj.2006.049734
27.
Rojas-Camayo J, Mejia CR, Callacondo D, et al. Reference values for oxygen saturation from sea level to the highest human habitation in the Andes in acclimatised persons. Thorax. 2018;73(8):776–778. doi: 10.1136/thoraxjnl-2017-210598. Epub 2017 Oct 20. PMID: 29054885.
